Predictive 3D modelling of erosion and deposition in ITER with ERO2.0: from beryllium main wall, tungsten divertor to full-tungsten device

Erosion and deposition is modelled with ERO2.0 for a hypothetical full-tungsten ITER for an ELM-free H-Mode baseline deuterium discharge. A parameter study considering seeding impurities (Ne, Ar, Kr, Xe) at constant percentages (0.05% to 1.0%) of the deuterium ion flux is done while neglecting their radiation cooling and core plasma compatibility. With pure deuterium plasma, tungsten main wall erosion is only due to charge exchange deuterium atoms and self-sputtering and there is only minor tungsten divertor sputtering. With a beryllium main wall, beryllium erosion is due to deuterium ions, charge exchange deuterium neutrals and self-sputtering. For this case, tungsten in the divertor is eroded by beryllium ions and self-sputtering. The simulations for full-tungsten device including seeded impurities leads to significant tungsten erosion in the divertor. In general, tungsten erosion, self-sputtering and deposition increase by factors larger than 50 at the main wall and 5000 in the divertor compared to pure deuterium plasma

Patient ABO blood type is a major predictor of a positive DAT following a transfusion reaction

Background: A direct antiglobulin test (DAT) checks for antibody or complement on the surface of RBCs and is often done following a transfusion reaction. While passive anti-A and anti-B antibodies are known to cause positive DATs, the extent this occurs following transfusion is unknown. Study Design and methods: DAT results, ABO type and blood product information was recorded on 1097 transfusion reactions at a large academic hospital over 8 years. The effect of patient blood type, product type and plasma compatibility of blood product transfused on DAT results were determined. Statistical significance was determined using Chi-squared testing. Results: Plasma compatibility of the product was a strong predictor of a positive DAT with plasma compatible transfusions having a 9.4% positive rate while plasma incompatible transfusions were positive 44% of the time (P<0.0001). Patient ABO blood type was a strong predictor of a positive DAT with Type O patients having 6.6% positive rate and non-O patients having a positive rate of 20.6% (P <0.0001). These results were significant for individual blood types as well. Type A, B or AB patients had higher DAT positive rates even when plasma incompatible transfusions were excluded from the analysis (P<0.0001). Platelets were significantly more likely to be associated with a positive DAT when compared to RBC transfusions. Conclusions: These results show plasma compatibility and ABO types are strong predictors of positive DAT results following a transfusion reaction. Anti-A and anti-B antibodies are estimated to account for about 50% of positive DATs in this study.

Development of a new HPLC method for wogonin in rat plasma: Compatibility of standard and test samples

In the current paper, an HPLC/UV method was developed and validated for determination of wogonin in plasma. Considerable attention was paid to the preparation of standard samples and factors affecting drug distribution. A preparation procedure was devised to simulate the conditions the drug is expected to experiencein vivowhile pointing to the shortcomings of previously published methods. The method was validated according to the FDA regulations and showed to be highly efficient and capable of extracting the drug and IS from the plasma accurately and precisely within the specified range of 50–500 ng mL−1. Further, the standard sample preparation of this method can be used as a guideline for other methods, particularly when highly hydrophobic drugs with considerable protein binding are involved and could be valuable in the field of bioanalysis to improve the reliability of methods.